EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms

Jan Stetka iD, Marc Usart, Lucia Kubovcakova, Shivam Rai, Tata Nageswara Rao iD, Joshua Sutter iD, Hui Hao-Shen, Stefan Dirnhofer, Florian Geier, Michael S Bader, Jakob R Passweg, Vania Manolova iD und 9 weitere

Blood · 09.02.2023

DOI: 10.1182/blood.2022017976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, online erschienen am 09.02.2023. Verfasst von Jan Stetka und 20 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Iron Deficiencies. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

JAK2-V617F mutation causes myeloproliferative neoplasms (MPN) that can manifest as polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF). PV patients at diagnosis already exhibited iron deficiency, whereas ET patients had normal iron stores. We examined the influence of iron availability on MPN phenotype in mice expressing JAK2-V617F and in mice expressing JAK2 with a N542-E543del mutation in exon 12 (E12). At baseline on control diet, all JAK2-mutant mouse models with PV-like phenotype displayed iron deficiency, although E12 mice maintained more iron for augmented erythropoiesis than JAK2-V617F mutant mice. In contrast, JAK2-V617F mutant mice with an ET-like phenotype had normal iron stores comparable to wildtype (WT) mice. On low-iron diet, JAK2-mutant mice and WT controls increased platelet production at the expense of erythrocytes. Mice with PV phenotype responded to parenteral iron injections by decreasing platelet counts and further increasing hemoglobin and hematocrit, whereas no changes were observed in WT controls. Alterations of iron availability primarily affected the pre-megakaryocyte erythrocyte progenitors (pre-MegE), which constitute the iron-responsive stage of hematopoiesis in JAK2-mutant mice. The orally administered ferroportin inhibitor vamifeport and the minihepcidin PR73 normalized hematocrit and hemoglobin levels in JAK2-V617F and E12 mutant mouse models of PV, suggesting that ferroportin inhibitors and minihepcidins could be used in the treatment of PV patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersPolycythemia VeraThrombocythemia, EssentialIron DeficienciesMiceAnimalsIronJanus Kinase 2MutationPhenotypeHemoglobins

Substanzen

IronJanus Kinase 2Hemoglobins

Autor:innen und Institutionen

  • Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Swiss Institute of Bioinformatics, Basel, Switzerland.
  • Division of Hematology, University Hospital Basel, Basel, Switzerland.
  • CSL Vifor, St. Gallen, Switzerland.

ORCID-Profile: Jan Stetka, Tata Nageswara Rao, Joshua Sutter, Vania Manolova, Timm Schroeder, Tomas Ganz, Elizabeta Nemeth, Antonella Nai, Clara Camaschella, Radek C Skoda

Zitieren

APA

Stetka, J., Usart, M., Kubovcakova, L., Rai, S., Rao, T. N., Sutter, J., Hao-Shen, H., Dirnhofer, S., Geier, F., Bader, M. S., Passweg, J. R., Manolova, V., Dürrenberger, F., Ahmed, N., Schroeder, T., Ganz, T., Nemeth, E., Silvestri, L., Nai, A., …, & Skoda, R. C. (2023). Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood.2022017976

Vancouver

Stetka J, Usart M, Kubovcakova L, Rai S, Rao TN, Sutter J, et al. Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms. Blood. 2023. doi:10.1182/blood.2022017976

BibTeX
@article{Stetka2023,
  author = {Stetka, Jan and Usart, Marc and Kubovcakova, Lucia and Rai, Shivam and Rao, Tata Nageswara and Sutter, Joshua and Hao-Shen, Hui and Dirnhofer, Stefan and Geier, Florian and Bader, Michael S and Passweg, Jakob R and Manolova, Vania and Dürrenberger, Franz and Ahmed, Nouraiz and Schroeder, Timm and Ganz, Tomas and Nemeth, Elizabeta and Silvestri, Laura and Nai, Antonella and Camaschella, Clara and Skoda, Radek C},
  title = {Iron is a modifier of the phenotypes of JAK2 -mutant myeloproliferative neoplasms},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017976}
}
Kostenlos starten →